Do you want to read an article? Please log in or register.
The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis
Glycemic Control
Related content
COMMENTED
Type 2 Diabetes
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis
Diabetes Obes Metab.
Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine M, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V
doi: 10.1111/dom.
COMMENTED
Diabetes - GeneralType 2 Diabetes
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
★ 2
Recommended and commented by
Prof. Dr emer. Josef Flammer, Faculty Member
BMJ
Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, Nicolucci A, Johnson DW, Tonelli M, Rossi MC, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque LI, Lloyd A, Ahmad N, Liu Y, Tiv S, Millard T, Gagliardi L, Kolanu N, Barmanray RD, McMorrow R, Raygoza Cortez AK, White H, Chen X, Zhou X, Liu J, Rodríguez AF, González-Colmenero AD, Wang Y, Li L, Sutanto S, Solis RC, Díaz González-Colmenero F, Rodriguez-Gutierrez R, Walsh M, Guyatt G, Strippoli GFM
doi: 10.1136/bmj.m4573
COMMENTED
Type 2 Diabetes
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Lancet.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS
doi: 10.1016/S0140-6736
Diabetes - GeneralGlycemic Control
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis
J Am Heart Assoc.
Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, Carbone S, Abbate A, Dixon DL
doi: 10.1161/JAHA.117.005686.
COMMENTED
Type 2 Diabetes
Glucagon-like peptide 1 receptor agonists and sodium glucose co-transporter 2 inhibitors as combination therapy for type 2 diabetes. A systematic review and meta-analysis
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Obes Metab.
Mantsiou C, Karagiannis T, Kakotrichi P, Malandris K, Avgerinos I, Liakos A, Apostolos Tsapas, Bekiari E
doi: 10.1111/dom.14108.
Type 2 Diabetes
Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis
Diabet Med.
Hussein H, Zaccardi F, Khunti K, Seidu S, Davies MJ, Gray LJ
doi: 10.1111/dme.
COMMENTED
Type 2 Diabetes
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Circulation.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK,
Wilding JPH, Sabatine MS
doi: 10.1161/CIRCULATIONAHA.
Diabetes - GeneralType 2 Diabetes
Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Front Endocrinol (Lausanne)
Zhang A, Luo X, Meng H, Kang J, Qin G, Chen Y, Zhang X
doi: 10.3389/fendo.2020.604250
Type 2 Diabetes
Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis
Cardiovasc Diabetol.
Castellana M, Procino F, Sardone R, Trimboli P, Giannelli G
doi: 10.1186/s12933-020-01067-8.